Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Padmaja, Paderu"'
Autor:
Shuying Yu, Padmaja Paderu, Annie Lee, Sami Eirekat, Kelley Healey, Liang Chen, David S. Perlin, Yanan Zhao
Publikováno v:
Microbiology Spectrum, Vol 10, Iss 3 (2022)
ABSTRACT Candida glabrata is poised to adapt to drug pressure rapidly and acquire antifungal resistance leading to therapeutic failure. Given the limited antifungal armamentarium, there is an unmet need to explore new targets or therapeutic strategie
Externí odkaz:
https://doaj.org/article/3fdadfd443934f87b8dd609df842311d
Autor:
Xin Hou, Kelley R. Healey, Erika Shor, Milena Kordalewska, Cristina Jiménez Ortigosa, Padmaja Paderu, Meng Xiao, He Wang, Ying Zhao, Li-Yan Lin, Yan-Hai Zhang, Yong-Zhe Li, Ying-Chun Xu, David S. Perlin, Yanan Zhao
Publikováno v:
Emerging Microbes and Infections, Vol 8, Iss 1, Pp 1619-1625 (2019)
ABSTRACTEchinocandin resistance in Candida glabrata poses a serious clinical challenge. The underlying resistance mechanism of a pan-echinocandin-resistant C. glabrata isolate (strain L74) was investigated in this study. FKS mutants carrying specific
Externí odkaz:
https://doaj.org/article/4617bf9f1b1d4a9d867399b3ce74b219
Autor:
Nathan Raabe, Yanan Zhao, Padmaja Paderu, Ryan K Shields, Cornelius J Clancy, Minh-Hong Nguyen
Publikováno v:
Open Forum Infectious Diseases. 9
Background Invasive candidiasis (IC) is associated with significant morbidity and mortality. Echinocandins (ECH; caspofungin (CAS), micafungin (MFG), anidulafungin (AFG)) are first line therapy for IC. ECH resistance has emerged widely, most commonly
Autor:
Kelley R. Healey, Padmaja Paderu, Xin Hou, Cristina Jimenez Ortigosa, Nicole Bagley, Biren Patel, Yanan Zhao, David S. Perlin
Publikováno v:
Journal of Fungi, Vol 6, Iss 3, p 143 (2020)
Invasive infections caused by the opportunistic pathogen Candida glabrata are treated with echinocandin antifungals that target β-1,3-glucan synthase, an enzyme critical for fungal cell wall biosynthesis. Echinocandin resistance develops upon mutati
Externí odkaz:
https://doaj.org/article/167ff5ae15ea416fa5cd371c81c5239e
Autor:
Wei Huang, Guojian Liao, Gregory M. Baker, Yina Wang, Richard Lau, Padmaja Paderu, David S. Perlin, Chaoyang Xue
Publikováno v:
mBio, Vol 7, Iss 3 (2016)
ABSTRACT Cryptococcus neoformans is a human fungal pathogen and a major cause of fungal meningitis in immunocompromised individuals. Treatment options for cryptococcosis are limited. Of the two major antifungal drug classes, azoles are active against
Externí odkaz:
https://doaj.org/article/a0ad3fbd5af340e1af74a174f7794498
Autor:
Yan-Hai Zhang, Yong-Zhe Li, Xin Hou, He Wang, Padmaja Paderu, Kelley R. Healey, Meng Xiao, Yanan Zhao, Erika Shor, Milena Kordalewska, Li-Yan Lin, David S. Perlin, Ying Zhao, Yingchun Xu, Cristina Jiménez Ortigosa
Publikováno v:
Emerging Microbes & Infections
Echinocandin resistance in Candida glabrata poses a serious clinical challenge. The underlying resistance mechanism of a pan-echinocandin-resistant C. glabrata isolate (strain L74) was investigated in this study. FKS mutants carrying specific mutatio
Autor:
Nicole Bagley, Cristina Jiménez Ortigosa, Padmaja Paderu, David S. Perlin, Yanan Zhao, Xin Hou, Biren Patel, Kelley R. Healey
Publikováno v:
Journal of Fungi, Vol 6, Iss 143, p 143 (2020)
Journal of Fungi
Volume 6
Issue 3
Journal of Fungi
Volume 6
Issue 3
Invasive infections caused by the opportunistic pathogen Candida glabrata are treated with echinocandin antifungals that target β-1,3-glucan synthase, an enzyme critical for fungal cell wall biosynthesis. Echinocandin resistance develops upon mutati
Autor:
John R. Wingard, Yoji Nagasaki, Yanan Zhao, David S. Perlin, Michele W. Sugrue, Helen Leather, Padmaja Paderu
Publikováno v:
Medical Mycology. 57:38-44
One critical factor impeding successful management of invasive aspergillosis (IA) is the lack of reliable biomarkers to assess therapeutic response. We hypothesized that changes in certain host biomarkers reflect the nature of infection status and di
Autor:
Karen Joy Shaw, Min Hee Lee, Padmaja Paderu, Cristina Jiménez-Ortigosa, Steven Park, Yanan Zhao, Annie Lee, David S. Perlin, Robert S. Mansbach
Publikováno v:
Antimicrobial Agents and Chemotherapy. 62
APX001 is a first-in-class, intravenous and orally available, broad-spectrum antifungal agent in clinical development for the treatment of life-threatening invasive fungal infections. The half-life of APX001A, the active moiety of APX001, is signific
Autor:
Yanan, Zhao, Min Hee, Lee, Padmaja, Paderu, Annie, Lee, Cristina, Jimenez-Ortigosa, Steven, Park, Robert S, Mansbach, Karen Joy, Shaw, David S, Perlin
Publikováno v:
Antimicrobial agents and chemotherapy. 62(10)
APX001 is a first-in-class, intravenous and orally available, broad-spectrum antifungal agent in clinical development for the treatment of life-threatening invasive fungal infections. The half-life of APX001A, the active moiety of APX001, is signific